News & SEC Filings

View the latest news and SEC filings

News

LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at the following conferences in June 2025: Jefferies Global Healthcare Conference Date: Wednesday, June

Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre ® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m.

LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call

SEC Filings

Date Form Filing Group

April 24, 2017

CORRESP

CORRESP

Other

April 24, 2017

CORRESP

CORRESP

Other

April 24, 2017

UPLOAD

UPLOAD

Other

PDF

April 21, 2017

CERTNAS

CERTNAS

Other

April 19, 2017

CERTNAS

CERTNAS

Other

April 19, 2017

Registration of certain classes of securities 12(b) of the Securities Exchange Act

8-A12B

Registration Statements

April 18, 2017

This filing is a pre-effective amendment to an F-1 filing

F-1/A

Registration Statements

April 18, 2017

Registration of depository shares evidenced by American Depository Receipts

F-6

Registration Statements

April 18, 2017

CORRESP

CORRESP

Other

Developing novel therapeutics for respiratory diseases

Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.